Skip to content
Disclosery

CAXTON CORP

Follow

13F filer, CIK 1388551, Princeton, NJ

CAXTON CORP reported $9,853,130 across 11 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-08-14. Its ten largest share positions make up 99.88% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000919574-25-004762

Changes against Q1 2025 are not shown: its report omitted holdings under a confidential treatment request (12 positions on file), so every position would read as new.

The filing omits holdings under a confidential treatment request (H8). A later amendment may add them.

Period
2025-06-30
Reported value
$9.85M
Holdings
11
Top 10 weight
99.88%
New
Sold out

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0000919574-25-004762, largest first. % of portfolio is the value over $9,853,131, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
RZLTREZOLUTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,318,967 shares; 2024Q4: 1,318,967 shares; 2025Q1: 1,318,967 shares; 2025Q2: 1,603,986 shares 1,603,986$7.15M72.6%The filing omitted confidential holdings, a later amendment may add them.Timeline
GLDSPDR GOLD TRQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 1,169 shares; 2025Q1: 1,298 shares; 2025Q2: 4,952 shares 4,952$1.51M15.32%The filing omitted confidential holdings, a later amendment may add them.Timeline
BRK-BBERKSHIRE HATHAWAY INC DELQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,151 shares; 2024Q4: 1,133 shares; 2025Q1: 467 shares; 2025Q2: 632 shares 632$307K3.12%The filing omitted confidential holdings, a later amendment may add them.Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 13,097 shares 13,097$263K2.67%The filing omitted confidential holdings, a later amendment may add them.Timeline
MIND MEDICINE MINDMED INCMIND MEDICINE MINDMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 34,073 shares; 2024Q4: 34,073 shares; 2025Q1: 34,073 shares; 2025Q2: 34,073 shares 34,073$221K2.24%The filing omitted confidential holdings, a later amendment may add them.
CMPXCOMPASS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 43,465 shares; 2024Q4: 43,465 shares; 2025Q1: 43,465 shares; 2025Q2: 43,465 shares 43,465$113K1.15%The filing omitted confidential holdings, a later amendment may add them.Timeline
BCAXBICARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 10,941 shares; 2024Q4: 10,941 shares; 2025Q1: 10,941 shares; 2025Q2: 10,941 shares 10,941$102K1.03%The filing omitted confidential holdings, a later amendment may add them.Timeline
KYTXKYVERNA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 22,981 shares; 2024Q4: 22,981 shares; 2025Q1: 22,981 shares; 2025Q2: 22,981 shares 22,981$70.6K0.72%The filing omitted confidential holdings, a later amendment may add them.Timeline
LXEOLEXEO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 17,851 shares; 2024Q4: 17,851 shares; 2025Q1: 17,851 shares; 2025Q2: 17,332 shares 17,332$69.7K0.71%The filing omitted confidential holdings, a later amendment may add them.Timeline
IKTINHIBIKASE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 16,393 shares; 2025Q1: 16,393 shares; 2025Q2: 16,393 shares 16,393$32K0.32%The filing omitted confidential holdings, a later amendment may add them.Timeline
CNTXCONTEXT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 18,403 shares; 2024Q4: 18,403 shares; 2025Q1: 18,403 shares; 2025Q2: 18,403 shares 18,403$12.1K0.12%The filing omitted confidential holdings, a later amendment may add them.Timeline

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000919574-25-004762 base2025-08-14acceptance time not in the bulk data set